NASDAQ: ALNYAlnylam Pharmaceuticals Inc Stock
$263.24+6.05 (+2.35%)
Updated Apr 30, 2025
ALNY Price
$263.24
Fair Value Price
N/A
Market Cap
$34.08B
52 Week Low
$144.73
52 Week High
$304.39
P/E
-120.75x
P/B
507.96x
P/S
13.36x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.25B
Earnings
-$278.16M
Gross Margin
85.6%
Operating Margin
-10.48%
Profit Margin
-12.4%
Debt to Equity
62.2
Operating Cash Flow
-$8M
Beta
0.89
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ALNY Overview
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ALNY's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ALNY
Ranked#43 of 462
Ranked#43 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important ALNY news, forecast changes, insider trades & much more!
ALNY News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ALNY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALNY is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ALNY is poor value based on its book value relative to its share price (507.96x), compared to the US Biotechnology industry average (4.45x)
P/B vs Industry Valuation
ALNY is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ALNY due diligence checks available for Premium users.
Valuation
ALNY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-120.75x
Industry
-162.28x
Market
29.18x
ALNY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
507.96x
Industry
4.45x
ALNY is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ALNY's financial health
Profit margin
Revenue
$593.2M
Net Income
-$83.8M
Profit Margin
-14.1%
ALNY's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ALNY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$4.2B
Liabilities
$4.2B
Debt to equity
62.2
ALNY's short-term assets ($3.30B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALNY's short-term assets ($3.30B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALNY's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ALNY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$94.7M
Investing
-$52.9M
Financing
$31.0M
ALNY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ALNY vs Biotech Stocks
Alnylam Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.